MiNK Therapeutics rises after data shows long-lasting remissions in tough cancers

Shares of drug developer MiNK Therapeutics INKT.O rise 2% to $13.93 premarket

Co says its experimental cell therapy, agenT-797, shows lasting benefits for patients with advanced cancers who had stopped responding to other treatments

INKT says patients who received agenT-797, either alone or with an existing immunotherapy drug, lived for a median of about 23 months

Some patients with tough-to-treat cancers, including testicular, thymoma, and gastric cancers, saw their disease controlled for more than two years - co

Doctors say that one patient with metastatic testicular cancer experienced a complete remission lasting over two years after receiving the combination therapy - INKT

Other patients with different cancers also saw their tumors shrink or stop growing for extended periods, co says

Up to last close, stock up 96% YTD